⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
IRD News
Opus Genetics, Inc. Common Stock
Form 8-K
sec.gov
IRD
Opus Genetics Announces Financial Results for Full Year 2025 and Provides Corporate Update
globenewswire.com
IRD
Opus Genetics to Present at Upcoming Investor Conferences in March 2026
globenewswire.com
IRD
Opus Genetics to Present at Upcoming Investor Conferences in March 2026
globenewswire.com
IRD
Opus Genetics Announces Initial Clinical Data from Phase 1/2 OPGx-BEST1 Gene Therapy Study at the Macula Society Annual Meeting
globenewswire.com
IRD
Opus Genetics Announces FDA Acceptance of Supplemental New Drug Application for Phentolamine Ophthalmic Solution 0.75% for the Treatment of Presbyopia
globenewswire.com
IRD
VTRS
Form 8-K
sec.gov
IRD
Opus Genetics Announces $25 Million Private Placement
globenewswire.com
IRD
Opus Genetics to Participate in Upcoming Medical and Industry Conferences in February 2026
globenewswire.com
IRD
Opus Genetics Launches Gene Therapy Clinical Trial for MERTK-related Retinitis Pigmentosa
globenewswire.com
IRD